A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
Inclusion Criteria:
Exclusion Criteria:
Natal, Rio Grande do Norte 59040-000, Brazil
Porto Alegre, Rio Grande do Sul 90020-090, Brazil
Porto Alegre, Rio Grande do Sul 91350-280, Brazil
Barretos/SP, São Paulo 14784-400, Brazil
São José do Rio Preto, São Paulo 15090-000, Brazil
Montreal, Quebec H2X 0A9, Canada
Shenzhen, Guangdong 518172, China
Shengyang, Liaoning 110042, China
Gorimedu, Puducherry 605006, India
Cherkasy, 18009, Ukraine